Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:EIGR

Eiger BioPharmaceuticals (EIGR) Stock Price, News & Analysis

Eiger BioPharmaceuticals logo

About Eiger BioPharmaceuticals Stock (NASDAQ:EIGR)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.30
$7.17
52-Week Range
N/A
Volume
137,800 shs
Average Volume
103,866 shs
Market Capitalization
$2.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Receive EIGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EIGR Stock News Headlines

Remembering John Harlin, Eiger Legend
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Eiger Biopharmaceuticals Inc (EIGRQ)
Eiger BioPharmaceuticals, Inc. (EIGRQ)
72C.SG,0P00015QPW,0 (72C.SG)
See More Headlines

EIGR Stock Analysis - Frequently Asked Questions

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) posted its earnings results on Thursday, November, 4th. The biotechnology company reported ($19.50) EPS for the quarter, missing analysts' consensus estimates of ($17.40) by $2.10. The biotechnology company had revenue of $3.04 million for the quarter, compared to analyst estimates of $2.54 million. Eiger BioPharmaceuticals had a negative trailing twelve-month return on equity of 332.49% and a negative net margin of 590.80%.

Shares of Eiger BioPharmaceuticals reverse split on the morning of Monday, January 8th 2024. The 1-30 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eiger BioPharmaceuticals investors own include Enovix (ENVX), Rambus (RMBS), Ginkgo Bioworks (DNA), COMPASS Pathways (CMPS), Toast (TOST), Globant (GLOB) and Saia (SAIA).

Company Calendar

Last Earnings
11/04/2021
Today
4/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:EIGR
Employees
56
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-96,780,000.00
Net Margins
-590.80%
Pretax Margin
-590.79%

Debt

Sales & Book Value

Annual Sales
$15.77 million
Price / Cash Flow
N/A
Book Value
$37.68 per share
Price / Book
N/A

Miscellaneous

Free Float
1,419,000
Market Cap
$2.55 million
Optionable
Optionable
Beta
1.83

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:EIGR) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners